Prognostic value of maspin mRNA expression in ERα-positive postmenopausal breast carcinomas
2003

Maspin mRNA Expression in Breast Cancer

Sample size: 105 publication Evidence: moderate

Author Information

Author(s): Bièche I, Girault I, Sabourin J-C, Tozlu S, Driouch K, Vidaud M, Lidereau R

Primary Institution: Centre René Huguenin, France

Hypothesis

The study investigates the prognostic value of maspin mRNA expression in ERα-positive postmenopausal breast carcinomas.

Conclusion

Maspin mRNA overexpression is associated with poor long-term outcomes in ERα-positive postmenopausal breast cancer patients.

Supporting Evidence

  • 54.3% of tumors showed altered maspin mRNA expression.
  • 31.4% of tumors showed maspin mRNA underexpression.
  • 22.9% of tumors showed maspin mRNA overexpression.
  • Patients with maspin-overexpressing tumors had a 5-year relapse-free survival of 41.8%.

Takeaway

This study looks at a gene called maspin in breast cancer and finds that when this gene is too active, it can mean worse outcomes for patients.

Methodology

Real-time quantitative RT–PCR was used to quantify maspin mRNA in tissue samples from breast cancer patients.

Limitations

The study is limited to a specific cohort of ERα-positive postmenopausal patients and may not generalize to other populations.

Participant Demographics

105 ERα-positive postmenopausal breast cancer patients, mean age 70.8 years.

Statistical Information

P-Value

0.0011

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600812

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication